Radius Health, Inc.RDUS presented positive top line data from the phase III ACTIVE (Abaloparatide Comparator Trial In Vertebral Endpoints) study on its lead candidate abaloparatide subcutaneous (SC). Radius Health is developing the daily self administered injection, abaloparatide SC, for